Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 145Parkinson Disease 4, Autosomal Dominant Lewy Body 120Melanoma 84Squamous Cell Carcinoma of Head and Neck 56Neoplasms 44Breast Neoplasms 41Stomach Neoplasms 39Colorectal Neoplasms 38Triple Negative Breast Neoplasms 37Neoplasm Metastasis 36Carcinoma, Renal Cell 36Ovarian Neoplasms 30Lung Neoplasms 30Head and Neck Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Transitional Cell 26Carcinoma, Hepatocellular 26Pancreatic Neoplasms 23Esophageal Neoplasms 20Endometrial Neoplasms 16Recurrence 15Prostatic Neoplasms 15Multiple Myeloma 15Fallopian Tube Neoplasms 15Carcinoma 14Sarcoma 13Lymphoma, Large B-Cell, Diffuse 13Small Cell Lung Carcinoma 12Lymphoma, Follicular 12Lymphoma, Non-Hodgkin 11

Interventions

Ribavirin 4ledipasvir, sofosbuvir drug combination 2Sofosbuvir 2telaprevir 1pembrolizumab 1peginterferon alfa-2a 1grazoprevir 1elbasvir-grazoprevir drug combination 1elbasvir 1Rapid Diagnostic Tests 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hepatitis C × pembrolizumab × Clear all
NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡